Navigation Links
Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
Date:9/7/2009

rships. In 2008, Research and Development expenditure was about EUR183 million, close to 19% of consolidated sales, which amounted to EUR971 million while total revenues exceeded EUR1 billion. Ipsen's shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Service de Reglement Differe" ("SRD") and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at http://www.ipsen.com.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales in excess of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

Ipsen Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are based on the Group's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Moreover, the targets described in this document were pre
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
2. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
3. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Japanese Cancer Association and Debiopharm Honour Japanese Research
8. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
9. Debiopharm and EPFL Establish an Oncology Chair
10. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
11. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... and CEO Marc Hedrick , M.D. will present live ... Thursday, December 4, 2014 TIME:    11:15 am PT ... or paste this URL into your browser,s address bar: ... to save time and receive event updates. ...
(Date:11/18/2014)... LA (PRWEB) November 17, 2014 ... build-to-order, open architecture blade-based and rackmount computing infrastructure, ... Tesla® K80 dual-GPU accelerator throughout its GPU-enabled blade ... pair of the company’s latest proprietary 80-lane Gen3 ... eight discrete NVIDIA Tesla K80 dual-GPU accelerator cards ...
(Date:11/18/2014)... American Process Inc. (Atlanta, GA) and ... with researchers at Georgia Institute of Technology, Clark ... USDA’s Forest Products Laboratory to develop ultra-strong, lightweight ... a rapidly emerging high performance nanomaterial extracted from ... replace heavy steel structures within cars, such as ...
(Date:11/18/2014)... Nov. 18, 2014 PDL BioPharma, Inc. (PDL) ... connection with the acquisition of Durata Therapeutics, Inc. by ... with the termination of PDL,s credit agreement with Durata, ... of $40 million, accrued interest, and prepayment and change ... a structured financing transaction with Durata in which PDL ...
Breaking Biology Technology:Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2
... Biomedtex Inc. (Pink,Sheets: BMDX.PK) ("The Company") a ... The Company,s mission is to identify, evaluate ... and healthcare solutions, and then,seek to capture and ... For more information visit us at http://WWW.BIOMEDTEX.COM ...
... Inverness Medical,Innovations (Amex: IMA ) today announced that ... Ltd, an Australian company traded on,the Australian Securities Exchange, ... of the issued shares in Panbio for AUD 0.65 ... share capital of,Panbio at approximately AUD 41 million, or ...
... are Honored ... Meeting, Laguna Niguel, LAGUNA NIGUEL, Calif., Oct. 8 ... CEO-only conference hosted by,Burrill & Company and Kleiner Perkins Caufield ... at an Awards Dinner held here Sunday,evening. For twenty ...
Cached Biology Technology:Inverness Medical Innovations Agrees to Acquire Panbio Ltd. 2Biotech Hall of Fame Inductees Announced 2Biotech Hall of Fame Inductees Announced 3Biotech Hall of Fame Inductees Announced 4Biotech Hall of Fame Inductees Announced 5Biotech Hall of Fame Inductees Announced 6
(Date:11/4/2014)... death at the right time might actually help boost ... could help in understanding animal populations, pest control and ... in the journal Trends in Ecology and Evolution ... that the kind of positive population effect an overall ... depends on the size and developmental stage of the ...
(Date:11/4/2014)... GABLES, Fla. (November 4, 2014) — Think about the ... ask: How do neighboring cells know that they are ... and how do these tissues find the correct place ... are answering these crucial questions. , In a new ... use to communicate with their surrounding neighbors, at the ...
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2The inside story: How the brain and skull stay together 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... that honey bees "self-medicate" when their colony is infected ... antifungal plant resins to ward off the pathogen. ... effort of its worker bees to collect these resins," ... NC State,s Department of Entomology and lead author of ...
... A proposed study could help determine if there is a ... facilities and having a higher risk of cancer, but challenges ... Research Council, the operating arm of the National Academy of ... that a pilot study be completed first to evaluate the ...
... Peninsula, such as the Iberian lynx, are under an increasingly ... and that can even survive in extremely arid environments. A ... ticks to adapt according to climate. The life cycle ... movement patterns of people and goods. These parasites and the ...
Cached Biology News:Bees 'self-medicate' when infected with some pathogens 2Report presents designs for study of cancer risks near US nuclear facilities 2Report presents designs for study of cancer risks near US nuclear facilities 3Ticks can adapt to the Spain's climatic diversity 2
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... designed to allow neomycin/kanamycin selection in ... loxP-PGK-gb2-neo-loxP template encodes the neomycin/kanamycin resistance ... (gb2) for expression of kanamycin resistance ... (PGK) for expression of neomycin resistance ...
... isolations. The kit provides a simple and ... from normal c lture using annexin V ... Ca2+-dependent phospholipid binding protein with high affinity ... Kit provides a simple and efficient means ...
... is tailored to highly enrich ... of rat spleen cells. Cells ... (or compatible 0.5 Tesla) immunomagnetic ... CD4+ T cell content of ...
Biology Products: